Pearl Quijada1, Hazel T Salunga1, Nirmala Hariharan1, Jonathan D Cubillo1, Farid G El-Sayed1, Maryam Moshref1, Kristin M Bala1, Jacqueline M Emathinger1, Andrea De La Torre1, Lucia Ormachea1, Roberto Alvarez1, Natalie A Gude1, Mark A Sussman2. 1. From the Integrated Regenerative Research Institute, Department of Biology, San Diego State University, CA (P.Q., H.T.S., J.D.C., F.G.E.-S., M.M., K.M.B., J.M.E., A.D.L.T., L.O., R.A., N.A.G., M.A.S.); and Department of Pharmacology, University of California at Davis (N.H.). 2. From the Integrated Regenerative Research Institute, Department of Biology, San Diego State University, CA (P.Q., H.T.S., J.D.C., F.G.E.-S., M.M., K.M.B., J.M.E., A.D.L.T., L.O., R.A., N.A.G., M.A.S.); and Department of Pharmacology, University of California at Davis (N.H.). heartman4ever@icloud.com.
Abstract
RATIONALE: Dual cell transplantation of cardiac progenitor cells (CPCs) and mesenchymal stem cells (MSCs) after infarction improves myocardial repair and performance in large animal models relative to delivery of either cell population. OBJECTIVE: To demonstrate that CardioChimeras (CCs) formed by fusion between CPCs and MSCs have enhanced reparative potential in a mouse model of myocardial infarction relative to individual stem cells or combined cell delivery. METHODS AND RESULTS: Two distinct and clonally derived CCs, CC1 and CC2, were used for this study. CCs improved left ventricular anterior wall thickness at 4 weeks post injury, but only CC1 treatment preserved anterior wall thickness at 18 weeks. Ejection fraction was enhanced at 6 weeks in CCs, and functional improvements were maintained in CCs and CPC+MSC groups at 18 weeks. Infarct size was decreased in CCs, whereas CPC+MSC and CPC parent groups remained unchanged at 12 weeks. CCs exhibited increased persistence, engraftment, and expression of early commitment markers within the border zone relative to combinatorial and individual cell population-injected groups. CCs increased capillary density and preserved cardiomyocyte size in the infarcted regions suggesting CCs role in protective paracrine secretion. CONCLUSIONS: CCs merge the application of distinct cells into a single entity for cellular therapeutic intervention in the progression of heart failure. CCs are a novel cell therapy that improves on combinatorial cell approaches to support myocardial regeneration.
RATIONALE: Dual cell transplantation of cardiac progenitor cells (CPCs) and mesenchymal stem cells (MSCs) after infarction improves myocardial repair and performance in large animal models relative to delivery of either cell population. OBJECTIVE: To demonstrate that CardioChimeras (CCs) formed by fusion between CPCs and MSCs have enhanced reparative potential in a mouse model of myocardial infarction relative to individual stem cells or combined cell delivery. METHODS AND RESULTS: Two distinct and clonally derived CCs, CC1 and CC2, were used for this study. CCs improved left ventricular anterior wall thickness at 4 weeks post injury, but only CC1 treatment preserved anterior wall thickness at 18 weeks. Ejection fraction was enhanced at 6 weeks in CCs, and functional improvements were maintained in CCs and CPC+MSC groups at 18 weeks. Infarct size was decreased in CCs, whereas CPC+MSC and CPC parent groups remained unchanged at 12 weeks. CCs exhibited increased persistence, engraftment, and expression of early commitment markers within the border zone relative to combinatorial and individual cell population-injected groups. CCs increased capillary density and preserved cardiomyocyte size in the infarcted regions suggesting CCs role in protective paracrine secretion. CONCLUSIONS:CCs merge the application of distinct cells into a single entity for cellular therapeutic intervention in the progression of heart failure. CCs are a novel cell therapy that improves on combinatorial cell approaches to support myocardial regeneration.
Authors: Jasmine M F Wu; Ying-Chang Hsueh; Hui-Ju Ch'ang; Chwan-Yau Luo; Li-Wha Wu; Hiromitsu Nakauchi; Patrick C H Hsieh Journal: Circ Res Date: 2014-11-14 Impact factor: 17.367
Authors: Manuel Alvarez-Dolado; Ricardo Pardal; Jose M Garcia-Verdugo; John R Fike; Hyun O Lee; Klaus Pfeffer; Carlos Lois; Sean J Morrison; Arturo Alvarez-Buylla Journal: Nature Date: 2003-10-12 Impact factor: 49.962
Authors: Konstantinos E Hatzistergos; Henry Quevedo; Behzad N Oskouei; Qinghua Hu; Gary S Feigenbaum; Irene S Margitich; Ramesh Mazhari; Andrew J Boyle; Juan P Zambrano; Jose E Rodriguez; Raul Dulce; Pradip M Pattany; David Valdes; Concepcion Revilla; Alan W Heldman; Ian McNiece; Joshua M Hare Journal: Circ Res Date: 2010-07-29 Impact factor: 17.367
Authors: Kenneth R Boheler; Robert N Joodi; Hui Qiao; Ondrej Juhasz; Amanda L Urick; Sandra L Chuppa; Rebekah L Gundry; Robert P Wersto; Rong Zhou Journal: Stem Cells Int Date: 2011-09-06 Impact factor: 5.443
Authors: Elena Cambria; Julia Steiger; Julia Günter; Annina Bopp; Petra Wolint; Simon P Hoerstrup; Maximilian Y Emmert Journal: Transfus Med Hemother Date: 2016-07-26 Impact factor: 3.747
Authors: Makoto Natsumeda; Victoria Florea; Angela C Rieger; Bryon A Tompkins; Monisha N Banerjee; Samuel Golpanian; Julia Fritsch; Ana Marie Landin; Nilesh D Kashikar; Vasileios Karantalis; Viky Y Loescher; Kostas E Hatzistergos; Luiza Bagno; Cristina Sanina; Muzammil Mushtaq; Jose Rodriguez; Marcos Rosado; Ariel Wolf; Kevin Collon; Louis Vincent; Anthony J Kanelidis; Ivonne H Schulman; Raul Mitrani; Alan W Heldman; Wayne Balkan; Joshua M Hare Journal: J Am Coll Cardiol Date: 2017-11-14 Impact factor: 24.094
Authors: Konstantinos E Hatzistergos; Dieter Saur; Barbara Seidler; Wayne Balkan; Matthew Breton; Krystalenia Valasaki; Lauro M Takeuchi; Ana Marie Landin; Aisha Khan; Joshua M Hare Journal: Circ Res Date: 2016-08-01 Impact factor: 17.367
Authors: Bryon A Tompkins; Wayne Balkan; Johannes Winkler; Mariann Gyöngyösi; Georg Goliasch; Francisco Fernández-Avilés; Joshua M Hare Journal: Circ Res Date: 2018-03-30 Impact factor: 17.367